Public Health · Informed Consent

Dr. Kirk Milhoan: A Refreshing Change at the Head of the CDC's Vaccine Advisory Committee

Dr. Kirk Milhoan, pediatric cardiologist and newly appointed head of the Advisory Committee on Immunization Practices (ACIP) at the Centers for Disease Control and Prevention, is no stranger to controversy. From the onset of the COVID-19 pandemic, he operated from a simple guiding principle: his role as a doctor was to "do no harm."

His appointment has drawn both strong support and fierce opposition — a fact that became clear almost immediately when he was fired from his pediatric cardiology practice within days of taking the role, only to be reinstated shortly after when a colleague publicly defended him. His story is, in many ways, a reflection of the broader tension currently playing out in American medicine between institutional compliance and individual clinical judgment.

A Record of Standing His Ground

When ivermectin and hydroxychloroquine were emerging as possible treatments for SARS-CoV-2, Dr. Milhoan participated in a panel discussion organized by the Pono Coalition for Informed Consent — a group that supported civil, open discussion about COVID-19 treatment options. Because of his participation, the Hawaii state medical board filed a complaint against Dr. Milhoan and Dr. Pang, the Maui District Health Officer, alleging that the two doctors were spreading misinformation.

Both doctors were subsequently cleared of all allegations. The episode is a useful lens through which to understand Dr. Milhoan: a physician willing to engage in good-faith scientific discussion even when it carries professional risk.

Fired, Then Reinstated

Shortly after his appointment as ACIP chair, Dr. Milhoan was terminated from his pediatric cardiology practice. His wife, Dr. Kim Milhoan, wrote publicly that his dismissal followed an overwhelming volume of calls to the organization demanding his firing due to his new role. As Dr. Milhoan described it in a recent interview: "I was becoming a public relations nightmare for them."

Within days, a colleague stepped forward in his defense and he was reinstated. The episode illustrates both the pressure now surrounding the ACIP chairmanship and the professional stakes involved for those willing to ask difficult questions about vaccine policy.

Bringing Back Informed Consent

Dr. Milhoan is a known vaccine advocate — but one who believes deeply in informed consent and the principle that each patient should be treated as an individual. This means weighing the risks and benefits for each person's health, lifestyle, and autonomy rather than applying a single population-level recommendation to every clinical encounter.

In a recent interview on the Dr. Drew Show, he described how he had long trusted the CDC, FDA, and NIH to thoroughly evaluate the safety and efficacy of vaccines. Once he accepted the ACIP chairmanship and began examining the underlying data directly, he found that standard was not consistently being met. The hepatitis B vaccine, for example, was reportedly studied for only seven days to assess long-term health effects.

Goals for His Time at ACIP

He has also raised specific concerns about combination vaccines, citing a 2018 meeting at which vaccines including DTP and MMR had been approved without any studies — including from Europe — evaluating their combined safety profile. His call for more rigorous long-term evidence is not anti-vaccine; it is a call for the same standard of scientific scrutiny applied to any other medical intervention.

Confusing Public Health with Science

One of the most important points Dr. Milhoan raised in his interview is the distinction — often blurred in practice — between public health decision-making and science. Decisions made to optimize population-level outcomes are not the same as decisions grounded in rigorous, individualized clinical evidence. Public health measures are often shaped by poor-quality data, limited long-term evaluation, and outcome tools that do not give individual providers what they need to make truly informed decisions for their patients.

This also includes incomplete data on race, ethnicity, income, and social and economic factors that profoundly shape health outcomes. In an ideal clinical world, the patient-provider relationship would be grounded in holistic, science-based data — and centered on what is genuinely best for the individual in front of the clinician, not the aggregate.